Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.25
Bid: 14.00
Ask: 14.50
Change: 0.00 (0.00%)
Spread: 0.50 (3.571%)
Open: 14.25
High: 14.25
Low: 14.00
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Venture Company

29 Mar 2006 07:02

Angle PLC29 March 2006 For Immediate Release 29 March 2006 ANGLE plc ('ANGLE' or 'the Company') New Venture Company: InnoMatica Ltd ANGLE plc ('ANGLE'), the venture management and consulting company specialisingin the commercialisation of technology, is pleased to announce the launch of itslatest venture company, InnoMatica Ltd ('InnoMatica'). In accordance with ANGLE's Progeny(R) process for creating new ventures,InnoMatica has secured intellectual property that is set to revolutionise theUS$1.2bn per annum global market for percussive power tools by reducing operatorexposure to vibration, the principal cause of medical conditions such asVibration White Finger (VWF). The technology has been developed over ten yearsby a team of leading engineers, academics from the University of Cambridge andmembers of the power tools industry. The scale of the vibration problem is substantial. In 2001, over 35% ofemployer's liability insurance claims were for Hand Arm Vibration Syndrome(HAVS), a debilitating condition caused by exposure to hand transmittedvibration. The Health and Safety Executive (HSE) estimates that there are around300,000 sufferers of VWF, the most common form of HAVS, in the UK, with around 2million people regularly exposed to high levels of vibration. Costs of settlinga single VWF claim can exceed £200,000. Since the implementation throughout Europe of the Physical Agents (Vibration)Directive (approved by the UK Parliament as The Control of Vibration at WorkRegulations, July 2005), employers have been bound to adhere to specific limitson employee exposure to vibration in the workplace. The only method ofsignificantly reducing the vibrations generated by percussive power tools, suchas road breakers, is by increasing the mass of the tool; yet practical andregulatory issues prevent the movement of such heavy tools. As a result,employers have had to either limit the time a single employee may use a tool oruse deliberately underpowered tools in order to comply with the regulations. InnoMatica holds the solution to this problem in the form of its Variable MassTechnology (VMtechnologyTM). This technology reduces tool vibration to a levelthat allows a single operator to use a powerful percussive power tool for up tofour times longer than existing products. This not only removes the need fortime limits or power reduction, but also provides the operator with a much saferand easier to use tool. In accordance with ANGLE's Progeny(R) process for creating new ventures, ANGLE'splan is to build a strong commercial offering, seeking a return on itsinvestment in the medium term. ANGLE expects to invest up to £400,000 in theProgeny(R) venture, which is presently wholly owned by ANGLE. Once InnoMaticahas exercised its option to acquire the technology, ANGLE's equity stake in theCompany will be 61%. ANGLE's Chief Executive, Andrew Newland, said: "The power tools and construction industries are worth US$1.2bn per annum, andthey have long awaited a solution to the injuries caused from vibration powertools. We are delighted to be at the forefront of a technology that dramaticallyenhances productivity, not only solving the financial and legislative issues butalso addressing human safety." Chief Technology Officer of InnoMatica, Dott. Giovanni Bisutti, said: "InnoMatica's technology provides a genuine new standard for health, safety,productivity and operator comfort in percussive power tools. We intend toaddress the major legislative and productivity issues currently facing theindustry." For further information ANGLE plc +44 1483 295830Andrew Newland, Chief ExecutiveStephen Bence, Director of New Ventures Buchanan Communications +44 20 7466 5000Richard Darby, Suzanne Brocks, James Strong, Amy Rajendran Note to editors: About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from officesin the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
27th Jan 201610:42 amRNSNotice of Interim Results
25th Jan 20167:00 amRNSUKE publishes evaluation of Parsortix
22nd Dec 20157:00 amRNSCompletion of Geomerics Transaction
15th Dec 20157:00 amRNSParsortix first commercial sales
10th Dec 20157:00 amRNSChange of FTSE Industry Classification Benchmark
30th Nov 20155:56 pmRNSHolding(s) in Company
17th Nov 20157:00 amRNSLung Cancer Research Publication
12th Nov 20152:17 pmRNSISSUE OF SHARE OPTIONS
14th Oct 20157:00 amRNSPatent Grant
30th Sep 20155:50 pmRNSResult of AGM
28th Sep 20157:00 amRNSOvarian cancer results
24th Sep 20157:00 amRNSProstrate cancer study published PLOS ONE Journal
9th Sep 20157:00 amRNSBREAST CANCER RESULTS PRESENTED AT CDX CONFERENCE
8th Sep 20153:54 pmRNSAnnual Report and Accounts and Notice of AGM
26th Aug 20151:48 pmRNSIssue of Equity and Total Voting Rights
23rd Jul 20157:00 amRNSFinal Results
20th Jul 20157:00 amRNSNotification of Preliminary Results
8th Jul 20157:00 amRNSAppointment Of Scientific Adviser
11th Jun 20157:00 amRNSBarts Prostate Cancer Update
3rd Jun 20157:00 amRNSAppointment of Scientific Adviser
26th May 20157:01 amRNSNew Patent Grants
21st Apr 20157:00 amRNSOvarian Cancer Update
20th Apr 20157:00 amRNSSidney Kimmel Cancer Centre
14th Apr 20157:00 amRNSIssue of Equity
4th Mar 20157:00 amRNSOffer to Shareholders
25th Feb 20151:11 pmRNSIssue of Equity
20th Feb 20154:05 pmRNSHolding(s) in Company
16th Feb 20157:01 amRNSMD Anderson Collaboration
16th Feb 20157:00 amRNSPlacing, Subscription and Offer
29th Jan 20157:00 amRNSInterim Results
27th Jan 20157:01 amRNS"Unprecedented Specificity" in Ovarian Cancer
23rd Jan 20157:00 amRNSCorporate Collaboration
23rd Jan 20157:00 amRNSPointMan collaboration with ANGLE plc
21st Jan 20153:00 pmRNSFurther information re Director's share transfer
19th Jan 20157:00 amRNSNotification of Interim Results
8th Jan 20157:00 amRNSCorporate Collaboration
15th Dec 20147:00 amRNSCancer Research Manchester Institute Publication
12th Nov 20147:00 amRNSFurther information re Director's share transfer
10th Nov 20147:00 amRNSIssue of Share Options
31st Oct 20147:00 amRNSADR PROGRAMME
21st Oct 20147:00 amRNSDirector's Share Transfer
17th Oct 20147:00 amRNSCollaboration with Barts Cancer Institute
17th Oct 20147:00 amRNSKey Opinion Leaders Report on Parsortix System
30th Sep 20144:30 pmRNSResult of AGM
30th Sep 20147:00 amRNSCollaboration with Thomas Jefferson University
25th Sep 20147:00 amRNSADR Programme, FDA Update and US Appointment
19th Sep 20147:00 amRNSBreast Cancer Collaboration
17th Sep 20147:00 amRNSCollaboration with Medical University of Vienna
8th Sep 20147:00 amRNSHamburg-Eppendorf Collaboration
4th Aug 20147:00 amRNSParsortix Granted Second US Patent

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.